Shanghai Essight Biotechnology

Shanghai Essight Biotechnology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of next-generation T-cell receptor (TCR) based therapies. Founded in 2023, the company leverages its proprietary TCR Miner™ discovery platform and soluble TCR engineering technology to develop TCR-directed T-cell engagers (TCRxCD3 bispecific antibodies) for the treatment of solid tumors and autoimmune diseases. Its lead candidate, ES502, is a first-in-class TCRxCD3 bispecific antibody targeting the RAS G12V mutation in complex with HLA, which received FDA clearance for Phase 1 clinical trials in March 2026. Essight Bio focuses on targeting intracellular antigens that are inaccessible to traditional antibody therapies, aiming to provide potent and specific treatment options for patients with high unmet medical needs.